1. Home
  2. BOOT vs IOVA Comparison

BOOT vs IOVA Comparison

Compare BOOT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boot Barn Holdings Inc.

BOOT

Boot Barn Holdings Inc.

N/A

Current Price

$131.92

Market Cap

3.7B

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$8.15

Market Cap

6.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOOT
IOVA
Founded
1978
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
6.7B
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
BOOT
IOVA
Price
$131.92
$8.15
Analyst Decision
Strong Buy
Buy
Analyst Count
17
9
Target Price
★ $180.67
$14.30
AVG Volume (30 Days)
963.8K
★ 13.8M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 25.00
14.84
EPS
★ 4.02
N/A
Revenue
★ $776,854,000.00
N/A
Revenue This Year
$14.57
$57.19
Revenue Next Year
$12.58
$43.78
P/E Ratio
$36.21
★ N/A
Revenue Growth
★ 14.59
N/A
52 Week Low
$110.53
$2.08
52 Week High
$210.25
$15.37

Technical Indicators

Market Signals
Indicator
BOOT
IOVA
Relative Strength Index (RSI) 53.71 33.26
Support Level $119.93 $7.85
Resistance Level $170.63 $9.36
Average True Range (ATR) 6.89 0.97
MACD 2.83 -0.78
Stochastic Oscillator 55.83 6.72

Price Performance

Historical Comparison
BOOT
IOVA

About BOOT Boot Barn Holdings Inc.

Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: